ArticleFrontiers in oncology2022

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.

Yanhua Yue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.